All In Biotech

Drug Trial Radar · NCT07442006

Glycemic Variability of Combination Therapies in T2DM

A Multicenter Study to Evaluate Efficacy and Safety

Last checked: Nov 20, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 178 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

178

Planned (sponsor's estimate)

Start

Oct 29, 2025

Primary completion

Mar 31, 2027

Study completion Mar 31, 2027

Sponsor

Lead sponsor
JW PharmaceuticalIndustry
Sponsor type
Industry
First posted
Mar 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Glycemic Variability of Combination Therapies in T2DM

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Interventions

  • Empagliflozin/MetforminDrug

    5/500 mg, 5/1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)

  • AnagliptinDrug

    100 mg, for 12 weeks (PO, BID)

  • MetforminDrug

    500 mg, 1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)

  • Empagliflozin/LinagliptinDrug

    10/5 mg, for 12 weeks (PO, QD)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change in Mean Amplitude of Glycemic Excursion (MAGE) from baseline to week 12Time frame: Baseline to week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Catholic University of Korea, Bucheon St. Mary's Hospital, Principal Investigator

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.